Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

NEXT STORY
Throne speech recognition of mental health and addiction support applauded by pan-Canadian health organizations
PREV STORY
Orgenesis and Theracell to Launch Point of Care Cell and Gene Therapy Centers within HYGEIA Group’s Hospital Network in Greece
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy

author_avatar
NASDAQ Market News

Proactive news headlines including Royal Road Minerals, Great Panther Mining, PharmaDrug, Codebase Ventures and Nextech AR Solutions

author_avatar
NASDAQ Market News

SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market

author_avatar
NASDAQ Market News